Trust Point’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,455
Closed -$245K – 533
2026
Q2
$245K Buy
+1,455
New +$216K 0.02% 398
2025
Q4
– Sell
-1,685
Closed -$237K – 494
2025
Q3
$237K Buy
+1,685
New +$228K 0.02% 430
2025
Q2
– Sell
-1,823
Closed -$202K – 449
2025
Q1
$202K Sell
1,823
-660
-27% -$83.6K 0.02% 442
2024
Q4
$339K Buy
2,483
+548
+28% +$67.8K 0.02% 391
2024
Q3
$223K Buy
1,935
+349
+22% +$47.8K 0.02% 475
2024
Q2
$218K Buy
+1,586
New +$218K 0.02% 461

Other funds holding NBIX

Trust Point's NBIX Position: Q3 2026 in Review

Trust Point sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,455 shares — an estimated $245K sold.

Trust Point first reported a position in NBIX in Q2 2024 and held it in 6 quarters. The position peaked at $339K in Q4 2024. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Trust Point reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • Trust Point sold 1,455 Neurocrine Biosciences shares in Q3 2026, an estimated $245K.
  • Trust Point first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 6 quarters.
  • Trust Point's Neurocrine Biosciences position peaked at $339K in Q4 2024.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.